HKEX Stock Code:
6996.HK
Corporate Profile

Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. Antengene has global rights on 10 assets, and Asia Pacific rights, including the Greater China region, on 5 assets. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, South Korea, Singapore, and Australia.
-
Press Releases
-
Aug 03,2022
Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101
Antengene Announces Research Collaboration with Celularity
Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018
Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting
Antengene Announces First Patient Dosed in the Phase I II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas
Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China
Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress
Antengene Announces Commercial Availability of XPOVIO® (Selinexor) Prescribed for the First Time Across Mainland China
Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines
Antengene to Participate in Three Upcoming Investor Conferences in May&June
Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting
Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Antengene’s Pivotal “MARCH” Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine
Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
Antengene Announces IND Approval in China for the Phase I Study of ATG-101 for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma
Antengene Announces XPOVIO® Regulatory Approval in Singapore
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference
First Patient Dosed in Australia in ATG-101 First-in-Human Trial
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
Antengene Announces NDA Approval by NMPA for XPOVIO®, China’s First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma
Antengene and XtalPi Announce AI-Driven R&D Collaboration
Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH)
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo (nivolumab) in Advanced Solid Tumors
Antengene Included in the MSCI Global Small Cap Indexes – MSCI China Index Constituent Stocks
Antengene Announces IND Approval in China for a Phase I II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma
Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day
Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021
Antengene to Release Preliminary Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of Peripheral T-Cell Lymphoma and NKT-Cell Lymphoma at the 2021
Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L14-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
-
-
Announcements & Circulars
-
Aug 09,2022
Discloseable Transaction Construction Agreement
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2022
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
REVENUE GROWTH FOR THE PERIOD FROM JANUARY 1, 2022 TO JUNE 30, 2022
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2022
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
Voluntary Announcement - Acknowledgement of CTN by the TGA for Phase I Clinical Trial of ATG-018 in Advanced Solid Tumors and Hematologic Malignancies
VOLUNTARY ANNOUNCEMENT ACKNOWLEDGEMENT OF CTN BY THE TGA FOR PHASE I CLINICAL TRIAL OF ATG-018 IN ADVANCED SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2022
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 1, 2022
Change of Venue of the Annual General Meeting to be Held on June 1, 2022
CHANGE OF VENUE OF THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 1, 2022
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2022
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING
Notification Letter and Request Form to Non-Registered Shareholders
NOTICE OF THE ANNUAL GENERAL MEETING
Form of Proxy for the Annual General Meeting
Notice of the Annual General Meeting
Proposals for General Mandates to Issue Shares and to Repurchase Shares, Re-Election of Directors and Notice of Annual General Meeting
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2022
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Change of Joint Company Secretary and Waiver from Scrict Compliance with Rules 3.18 and 8.17 of the Listing Rules
Voluntary Announcement - IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
VOLUNTARY ANNOUNCEMENT IND APPROVAL IN CHINA FOR A PHASE II STUDY OF ELTANEXOR (ATG-016) IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES
CHANGE OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Announcement of Annual Results for the Year Ended December 31, 2021
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2021
VOLUNTARY ANNOUNCEMENT IND APPROVAL IN CHINA FOR THE PHASE I STUDY OF ATG-101 FOR THE TREATMENT OF SOLID TUMORS AND NON-HODGKIN LYMPHOMA
TGA IN AUSTRALIA APPROVES XPOVIO (SELINEXOR) FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND TRIPLE CLASS-REFRACTORY MULTIPLE MYELOMA
NOTICE OF DATE OF BOARD MEETING
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022
VOLUNTARY ANNOUNCEMENT APPROVAL OF NDA BY THE SINGAPORE HSA FOR XPOVIO (SELINEXOR) FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND DIFFUSE LARGE B-CELL LYMPHOMA IN THREE INDICATIONS
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022
VOLUNTARY ANNOUNCEMENT NMPA APPROVAL OF IND APPLICATION IN CHINA FOR ATG-010 (SELINEXOR) IN COMBINATION WITH R-GDP (SR-GDP) FOR THE TREATMENT OF RRDLBCL IN A GLOBAL PHASE 2/3 STUDY
ADOPTION OF THE 2022 RESTRICTED SHARE UNIT SCHEME
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
GRANT OF SHARE OPTIONS
VOLUNTARY ANNOUNCEMENT NMPA GRANTED MARKETING APPROVAL FOR SELINEXOR (ATG-010) IN CHINA
RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021
VOLUNTARY ANNOUNCEMENT APPROVAL OF THE PHASE I/II STUDY OF SELINEXOR (ATG-010) IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN CHINA
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021
VOLUNTARY ANNOUNCEMENT APPROVAL OF NMPA FOR PHASE IB STUDY OF ATG-008 (ONATASERTIB) IN COMBINATION WITH ATG-010 (SELINEXOR) IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
VOLUNTARY ANNOUNCEMENT ANTENGENE RECEIVED U.S. FDA APPROVAL OF IND FOR PHASE I TRIAL OF ATG-101 IN SOLID TUMORS AND NON-HODGKIN LYMPHOMAS
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021
VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE
Notification Letter and Request Form to Non-Registered Shareholders
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021
VOLUNTARY ANNOUNCEMENT ACKNOWLEDGEMENT OF CTN BY THE TGA FOR PHASE I CLINICAL TRIAL OF ATG-101 IN SOLID TUMORS AND NON-HODGKIN LYMPHOMAS
SUPPLEMENTAL ANNOUNCEMENT CANCELLATION OF GRANT OF CERTAIN SHARE OPTIONS
GRANT OF SHARE OPTIONS
VOLUNTARY ANNOUNCEMENT APPROVAL OF THE PHASE II STUDY OF SELINEXOR BY NMPA FOR THE TREATMENT OF MYELOFIBROSIS IN CHINA
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021
NOTICE OF DATE OF BOARD MEETING
VOLUNTARY ANNOUNCEMENT APPROVAL OF NDA BY THE MFDS FOR ATG-010 (SELINEXOR) FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND DIFFUSE LARGE B-CELL LYMPHOMA
VOLUNTARY ANNOUNCEMENT THE SUBMISSION OF NDA FOR SELINEXOR IN TAIWAN FOR THE TREATMENT OF THREE INDICATIONS IN HEMATOLOGIC MALIGNANCIES
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2021
VOLUNTARY ANNOUNCEMENT AN UPDATE ON LATEST DEVELOPMENTS
(1) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 18, 2021; (2) RETIREMENT OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR; AND (3) APPOINTMENT OF EXECUTIVE DIRECTORS
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021
SUPPLEMENTAL CIRCULAR PROPOSED ELECTION OF EXECUTIVE DIRECTORS AND SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING
SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING
REVISED FORM OF PROXY FOR THE 2020 ANNUAL GENERAL MEETING
Notification Letter and Request Form to Non-Registered Shareholders
(1)RETIREMENT OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR (2)WITHDRAWAL OF ORDINARY RESOLUTIONS AT THE AGM (3)NOMINATION OF EXECUTIVE DIRECTORS AND (4)ADDITIONAL RESOLUTIONS TO BE PROPOSED AT THE AGM
VOLUNTARY ANNOUNCEMENT ENTERING INTO WORLDWIDE EXCLUSIVE LICENSE AGREEMENT WITH CALITHERA BIOSCIENCES, INC.
VOLUNTARY ANNOUNCEMENT NMPA APPROVAL OF IND APPLICATION FOR A PHASE IB/II CLINICAL TRIAL OF ELTANEXOR IN ADVANCED SOLID TUMORS
VOLUNTARY ANNOUNCEMENT NMPA APPROVAL OF IND APPLICATION FOR A PHASE III CLINICAL TRIAL OF SELINEXOR IN ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021
VOLUNTARY ANNOUNCEMENT BUILDING OF THE DRUG DISCOVERY AND MANUFACTURING CENTER FOR ANTIBODY BIOLOGICS IN HANGZHOU QIANTANG NEW AREA
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
NOTICE OF THE ANNUAL GENERAL MEETING
FORM OF PROXY FOR THE 2020 ANNUAL GENERAL MEETING
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
VOLUNTARY ANNOUNCEMENT NMPA APPROVAL OF IND APPLICATION FOR ATG-019 IN PATIENTS WITH ADVANCED SOLID TUMORS OR NON-HODGKIN'S LYMPHOMA
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020
RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
NOTICE OF DATE OF BOARD MEETING
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021
GRANT OF SHARE OPTIONS
GRANT OF SHARE OPTIONS
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF NDA BY THE NMPA FOR ATG-010 (SELINEXOR) FOR THE TREATMENT OF RRMM (
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
VOLUNTARY ANNOUNCEMENT FDA APPROVAL OF XPOVIO (SELINEXOR) AS A TREATMENT FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST ONE PRIOR THERAPY
VOLUNTARY ANNOUNCEMENT APPROVAL OF IND APPLICATION IN CHINA FOR A PHASE 3 CLINICAL TRIAL OF ATG-010 (SELINEXOR)
PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
VOLUNTARY ANNOUNCEMENT THE GROUP'S DOMESTIC OPERATING ENTITY RECEIVED GOVERNMENT GRANT IN THE PRC
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
VOLUNTARY ANNOUNCEMENT THE SUBMISSION OF NDAS FOR XPOVIO (SELINEXOR) IN MULTIPLE APAC MARKETS
VOLUNTARY ANNOUNCEMENT THE GROUP'S DOMESTIC OPERATING ENTITY RECEIVED GOVERNMENT GRANT IN THE PRC
VOLUNTARY ANNOUNCEMENT THE APPROVAL OF CLINICAL TRIAL OF ATG-016 FOR THE TREATMENT OF MDS IN THE PRC
ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS
SIXTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Audit Committee - Terms of Reference
Nomination and Corporate Governance Committee - Terms of Reference
Remuneration Committee - Terms of Reference
List of Directors and their Roles and Functions
GLOBAL OFFERING
GLOBAL OFFERING
GREEN APPLICATION FORM
PHIP (1st submission)
Application Proof (1st submission)